Capital raising and
ASX dual listing
- Cameron Partners advised Pacific Edge in relation to its NZ$104m capital raising and ASX dual listing
- The placement was heavily subscribed with New Zealand, Australian, and global institutional investors participating in the transaction
- Pacific Edge develops pioneering cancer diagnostics tools and is commercialising its Cxbladder diagnostics product suite in New Zealand, the US, and globally
- This transaction was an Equity Market Transaction of the Year finalist at the INFINZ industry awards held in 2022
